Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of its lead candidate, bempikibart (ADX-914). The clinical-stage biotech ...

In a report released on April 16, Thomas Smith from Leerink Partners maintained a Hold rating on Q32 Bio (QTTB – Research Report). The ...

Q32 Bio (QTTB) announced that the company has dosed the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory ...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc. (QTTB) on Tuesday reported a loss of $14.2 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a loss ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-reports-fourth-quarter-2024-financial-results-and-provides-corporate ...

SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage ...